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ABSTRACT 
PURPOSE 
Radiotherapy induced xerostomia (RIX) is the most common permanent side effect 
of radiotherapy (RT) to the head and neck (H&N). 
There is no effective topical treatment.  
LMS-611 is a mimetic of a natural lamellar body which prevents thick secretions like 
saliva from congesting organs.  
Primary objective - assess saliva properties before and during RT to the H&N. 
Secondary objectives - re-assess saliva properties with the addition of LMS-611, 
measure inter-patient variability, correlate patient reported symptoms with 
laboratory measurements and design subsequent first-in-human clinical trial of LMS-
611. 
METHODS 
Patients with H&N cancer receiving RT as primary treatment were recruited.  
Patients completed the Groningen RIX (GRIX) questionnaire and provided saliva 
samples at baseline, weeks 2, 4 and 6 of RT. Saliva adhesiveness and viscosity was 
tested by measuring time taken to travel 5cm down an inclined plane. 
RESULTS 
30 patients were enrolled.  
The inclined plane test (IPT) results (seconds) were as follows: baseline 31.3, week-2: 
49.7, week-4: 51.1, week-6: 55.7. Wide inter-patient variability was seen at baseline.  
GRIX scores increased as RT progressed.  Spearman rank correlation coefficient of 
inclined plane tests with GRIX scores was -0.06 at baseline, week-2 0.25, week-4 0.12 
and week-6 0.08.  
LMS-611 concentrations of 10mg/ml and 20mg/ml significantly reduced IPT times on 
saliva samples. 
CONCLUSIONS 
Saliva becomes more visco-adhesive and RIX worsens as RT progresses. There is little 
correlation between objective and subjective measures of RIX. The addition of LMS-
611to thick, sticky saliva restores its fluidity ex-vivo.  This warrants in-vivo analysis of 
the effect of LMS-611 upon RIX.  
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INTRODUCTION  
Radiotherapy (RT) or chemo radiotherapy (CRT) is well established as an alternative 
to surgery in squamous cell carcinoma (SCC) of the head & neck (H&N), with the dual 
aims of tumour cure and organ preservation [1]. Unfortunately, high doses of 
radiation are needed for tumour control; so long term sequelae of radiotherapy are 
frequently observed and impact significantly upon patients’ quality of life [2-4]. 
 
Radiotherapy induced xerostomia (RIX) is the most commonly reported late and 
permanent side effect of RT to the H&N [5]. RT preferentially damages the fluid 
secreting serous cells, rather than the mucin secreting cells, of the salivary glands, so 
patients experience a build-up of thick, sticky mucus and a dry mouth [6]. This can 
cause discomfort, taste alteration, speech and swallowing difficulties and accelerates 
dental caries [7].  
 
There is currently no effective topical treatment for RIX and a Cochrane review 
(2011) concluded that ‘Well designed, adequately powered randomized controlled 
trials of topical interventions for dry mouth are required to provide evidence to guide 
clinical care’ [8]. 
 
The changing epidemiology of H&N cancer, mainly due to a rise in oropharyngeal 
cancer caused by human papilloma virus means that patients are often younger with 
little co-morbidity [9].   
This group have a significantly improved response to treatment and overall survival 
[10-12] and will therefore live much longer with the consequences of treatment. [13, 
14]   With no effective topical agent, there remains an unmet clinical need for this 
group who will experience RIX to some degree over a long period of time. 
 
Reducing xerostomia with parotid sparing intensity modulated radiotherapy (IMRT) 
has resulted in modest improvements in observer-rated and patient reported 
xerostomia. Despite this, grade 2 (Radiation Therapy Oncology Group scale) or 
worse, xerostomia rates of 40% are typical at 12 months post IMRT.  [15, 16] 
Clinically significant RIX remains a problem therefore for many patients.  
 
Lamellar bodies have surface active properties and are an essential lubricant of the 
body’s tissues, preventing mucosal surfaces from sticking to each other and sticky 
secretions, like mucous and thick saliva, from congesting the hollow organs.  LMS-
611 is a multi-lipid mimetic of a naturally occurring lamellar body with an identical 
3D microstructure and biophysical properties to the natural substance.  A small, 
pilot, ex-vivo study, has previously shown that LMS-611 has the potential to reduce 
the ‘stickiness’ of oral cavity secretions from patients following radiation for H&N 
cancer [unpublished data] with its mode of action being biophysical rather than 
pharmacological. 
 
This pre-clinical study of LMS-611 was designed as an ex-vivo, proof of concept study 
and as a preparatory step towards a clinical study of LMS-611 in H&N cancer patients 
with RIX.   
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MATERIALS & METHODS  
 
Participants 
Patients with H&N cancer, who were scheduled to commence radical RT or CRT as 
primary treatment, were recruited to this single centre study.  
Eligible patients were 18 years or older and were judged to be at high risk of 
radiation induced xerostomia.  Exclusion criteria included known pre-existing 
xerostomia, use of any other investigational drug or product within 30 days and 
primary surgery (other than neck dissection alone) for SCC H&N.   
The protocol was approved by the national South West Wales Research Ethics 
Committee (MREC 13/WA/0153). Written informed consent was obtained from all 
participants. The study was sponsored by NHS Greater Glasgow and Clyde and 
funded by Lamellar Biomedical Limited (LBL). The study was conducted according to 
the principles of Good Clinical Practice and the 1964 Declaration of Helsinki. 
 
Procedures     
All patients received radical RT or CRT delivered with volumetric modulated arc 
therapy (VMAT). Gross tumour and the entirety of involved nodal levels received 
65Gy/30# over 6 weeks. Prophylactic dose to areas considered at high risk of occult 
disease was 54Gy/30# over 6 weeks.  Selection and delineation of target volumes 
was carried out according to international guidelines [17]. Cisplatin was delivered at 
100mg/m2 on day 1 and 22 of treatment for those receiving concurrent 
chemotherapy. 
Whole, unstimulated saliva samples and xerostomia questionnaires were collected 
from patients prior to radiotherapy (baseline) then 2 weeks, 4 weeks and 6 weeks 
into radiotherapy.  
Saliva adhesiveness and viscosity was tested by LBL using the inclined plane test (IPT) 
and by measuring surface tension (pendant drop) and contact angle (sessile drop) by 
goniometry.  
The IPT measures the time taken for saliva to travel 5 cm down an inclined plane (IP), 
held at 90 degrees to the horizontal.  This is used as a marker of saliva 
viscosity/adhesiveness where short transit times indicate less visco-adhesive saliva 
and longer times the converse.  Saliva samples were stored between 2-8°C before 
being removed from refrigerated storage and allowed to reach ambient room 
temperature prior to carrying out the IPT. All samples were tested within 5 days of 
production by the patients. Some samples were so visco-adhesive that even after 
several minutes there was no movement down the slope. In these cases the IP times 
were truncated at 60 seconds. 
Surface tension and contact angle measurements were taken using a KSV Theta 
CAM101 goniometer operating with OneAttension software.   
Patient reported xerostomia scores were collected using the Groningen 
Radiotherapy-Induced Xerostomia Questionnaire (GRIX) [18].  This is a validated 14 
item questionnaire which asks about dry mouth and sticky saliva during the day and 
night.  All scores were converted linearly to a 0-100 scale where higher scores 
represent more xerostomia. 
The primary objective was to measure the adhesive and viscoelastic properties of 
saliva samples pre and post RT to the H&N area. Secondary objectives were to 
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validate the findings of the pilot study with further ex-vivo efficacy data on differing 
concentrations of LMS-611, to measure the inter-patient differences in saliva 
properties, to correlate patient reported symptoms with laboratory measurements, 
and to inform the design of the subsequent clinical study. 
 
Statistical Analysis 
Continuous variables are summarised as mean, standard deviation, median, 
interquartile range and range, or a subset of these. Categorical variables are 
summarised as number and percentage per category. Violin plots are used to 
present the results at each time point. 
Values at follow up have been compared to baseline values and values at the 
previous visit using paired Wilcoxon tests.  
The relation between GRIX scores and other results is described using Spearman 
correlation coefficients with bootstrap 95% confidence intervals calculated from 
10000 bootstrap samples. 
In the IPT, there are many truncated times where the sample did not travel the full 
distance within the observed time. Therefore the results of the IPT have been 
additionally analysed as survival data, considering travelling the full distance as the 
event of interest, and any recorded time of 60 seconds as censored observation. The 
relation of other variables to the IPT results has been analysed using proportional 
hazards models accounting for repeated measurements within a patient. 
P-values have not been adjusted for multiple testing. 
All analyses have been carried out in R version 3.0.1[19].  
 
Role of the Funding Source 
The funding source (Lamellar Biomedical Ltd) carried out the laboratory tests on the 
saliva samples obtained. 
All laboratory work was performed at Lamellar Biomedical in compliance with the 
QMS system in accordance with ISO 9001:2008, ISO 13485:2003 and 21 CFR Part 
820.  
The corresponding author had full access to all the data in the study and final 
responsibility for the decision to submit for publication. 
RESULTS  
30 patients were recruited to the study between September 2013 and April 2014.  
29 patients completed the GRIX questionnaires and provided saliva samples at 
baseline and weeks 2, 4 and 6 of RT. One patient died from pneumonia during week 
3 of RT treatment and therefore did not complete the study beyond week 2. 
 
Demographics 
Patient demographics are summarised in table 1.  All patients had a pathologically 
confirmed diagnosis of SCC of the oropharynx with staging carried out as per local 
protocol with examination under anaesthetic, CT and MRI as indicated.   
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Saliva Adhesiveness and Viscosity Tests 
INCLINED PLANE TEST: 
The IPT results are summarised in table 2 and figure 1. This demonstrates increasing 
time taken for the IPT, and therefore increasing saliva adhesiveness and viscosity, 
when RT is commenced. The increase was significant from baseline to week-2, 
p=0.001. Values increase only moderately from week-2 to week-4 and from week-4 
to week-6 with p=0.250 and p=0.297 respectively.  
Wide inter-patient variability with a large range of values at baseline was observed. 
This variability appeared to decrease as treatment continued. This is at least partly 
due to the values being truncated at 60 seconds. 
The number of values included at each time point is less than the original sample size 
as not all saliva samples were suitable for testing. Some samples were so viscous that 
it was not possible for them to be handled in the laboratory and hence were 
excluded from the inclined plane test. 
SURFACE TENSION AND CONTACT ANGLE: 
As the volume of each sample directly impacted the level of testing performed a test 
priority was established: IP measurements were prioritised then surface tension and 
contact angle measurements would be assessed if possible. 
Where samples did not allow analysis, it was recorded.  
Analysis of the surface tension and contact angle of patient saliva proved to be 
particularly challenging due to the nature of the saliva samples received. Several 
samples presented both quantitative and qualitative limitations which restricted the 
analysis of both surface tension and contact angle measurements. 
As a result of this the number of samples that underwent goniometry assessment to 
assess surface tension and contact angle was limited.  
The results of contact angle and surface tension measurements taken on untreated 
saliva samples are not included here as meaningful interpretation is not possible due 
to the limitations described above. 
  
Fig. 1 Violin plots of the time taken to descend the IP against treatment duration. 
P-values refer to the comparison with previous visit by wilcoxon test 
 
Inclined Plane Tests with Addition of LMS-611  
Table 3 summarises, for each time point of assessment, the time taken for saliva to 
descend the IP where saline or LMS-611 has been added. 
As previously described, the time taken for untreated saliva to descend the IP 
increased from baseline to week-6, indicating increasing saliva adhesiveness and 
viscosity; this acted as the control.  
The addition of saline or LMS-611 at concentrations of 2.5mg/ml and 5mg/ml to the 
saliva samples did not reduce IPT times. However, when LMS-611 at concentrations 
of 10mg/ml and 20mg/ml were added significant reductions were seen in the IPT at 
each time point, as seen in the video of the IPT [Online Resource 1, Addition of LMS-
611 to RIX Saliva] 
Analysing the time to descend the IP as survival data separately for each time point 
(not shown) and overall adjusting for week of radiotherapy (table 4) demonstrates 
these statistically significant differences. The hazard ratio refers to the likelihood of 
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saliva travelling the 5cm; therefore a small hazard ratio indicates stickier saliva. 
Interestingly the addition of saline or LMS-611 2.5mg/ml to saliva seems to produce 
significantly stickier saliva than no treatment.  It is difficult to account for this effect. 
 
Patient Reported Xerostomia 
Patient reported xerostomia scores collected using the GRIX questionnaire are 
summarised in figure 2.  GRIX scores increased from one time point to the next as RT 
progressed. There is a statistically significant increase (p<0.001) from baseline to 
week-2 then week-2 to week-4 of RT with only a small further increase from week-4 
to week-6.  RIX scores demonstrated modest inter-patient variability at baseline with 
a wide range of scores observed. This variability remained constant throughout 
treatment.     
 
Fig. 2 Violin plots of GRIX Scores by treatment duration. P-values refer to the 
comparison with the previous visit by wilcoxon test. 
 
Correlation of Saliva Adhesiveness/Viscosity with Xerostomia Scores 
The IPT results were correlated with patient reported GRIX scores obtained for all 
time points.  No relevant correlation was seen between the 2 measurements, with 
Spearman Correlation Co-efficient of -0.06 (-0.43 – 0.33, 95% CI) at baseline; 0.25 (-
0.18 – 0.60, 95% CI) at week 2; 0.12 (-0.33 – 0.54, 95%CI) at week 4 and 0.08 (-0.39 – 
0.52, 95% CI) at week 6. 
Treating the IPT results as survival data, a model predicting the IPT results from the 
GRIX scores adjusting for time did not show a significant relationship (hazard ratio of 
0.990, 95% confidence interval 0.975 – 1.004, p=0.170). 
 
DISCUSSION 
RIX is the most frequently reported late toxicity following RT to the H&N area. It 
remains a clinically significant problem for many patients despite advances in 
radiation technology [15, 16] and there is currently no effective topical treatment 
[8].  The aim of this study was to assess viscosity and adhesiveness of saliva before 
and during RT to the H&N area and evaluate whether addition of LMS 611 changed 
these properties.  Inter-patient variability in saliva properties was also examined and 
the objective and subjective measurements of RIX correlated.  
 
Patient characteristics are as expected for locally advanced SCC of the H&N, with 
more males than females and most patients receiving combined chemoradiotherapy 
suggesting that the results are applicable to this group of patients generally. 
 
As expected and previously reported, saliva adhesiveness and viscosity increased as 
RT treatment progressed [5, 20]. The largest difference in saliva properties was 
observed between baseline and 2 weeks into RT, suggesting that the serous cells of 
the salivary glands are affected by the relatively low doses of radiation received in 
the first two weeks of RT. This is in keeping with previous work demonstrating a 
sharp reduction in salivary flow rates during the first week of RT delivered with 
conventional fractionation [5, 6, 20-25]. The mechanism behind this is thought to be 
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due to early damage to the plasma membrane in acinar cells rather than cell death 
which occurs later in the course of RT damage [26].  
 
Wide inter-patient variability in saliva properties was observed pre-treatment; this 
may be due to age, medication [27-29] or smoking. [30, 31] These possible 
confounding factors were not explored further. This variability lessened with time as 
the entire sampled population developed RIX. This was at least partly due to a ceiling 
effect, since there were an increasing number of samples that did not travel the full 
distance within 60 seconds as RT progressed. 
 
The GRIX questionnaire was chosen for this study as it specifically includes questions 
about sticky saliva, which is the component of RIX that LMS-611 is most likely to 
influence. It has been previously validated for use in RIX and is currently being used 
in a study in the USA to assess the impact of ‘Acetylcysteine Rinse in Reducing Saliva 
Thickness and Mucositis in Patients with Head and Neck Cancer Undergoing 
Radiation Therapy’ [32], i.e. in the same setting as this study.  GRIX scores indicate 
that, subjectively, xerostomia worsened as patients went through RT. Significant 
differences were seen between pre-treatment scores and each subsequent time 
point. The largest differences reported in RIX occurred between baseline and week-2 
then week-2 and week-4.  There was little further worsening of patient reported 
xerostomia between week-4 and 6 of RT.  Again, this may reflect high sensitivity of 
salivary glands to relatively low doses of radiation delivered during the initial weeks 
of treatment. 
Most of the literature reports on established RIX post RT and there appears to be 
only one previous report describing worsening quality of life due to RIX during RT 
[33].  However, that study used a non-validated, physician reported assessment tool 
whereas a patient reported score such as the GRIX questionnaire is generally 
accepted as the preferred measure [34]. Most studies assessing interventions for RIX 
are carried out in the late phase of xerostomia. As demonstrated in this study 
however, xerostomia does occur in the acute phase and therefore it is also valid to 
evaluate a novel intervention for RIX during RT as done here. 
 
Some inter-patient variability in GRIX scores is noted at each time point. This 
variability remains constant over the course of RT and is likely to reflect differences 
in patients’ perception of the symptom. Significant variation in reporting of 
xerostomia has been previously documented in this setting [21, 35] and also in the 
palliative care setting where dry mouth is also a common symptom [36]. 
 
No relevant correlation was observed between the objectively assessed saliva 
properties and patient reported xerostomia questionnaires. This is the first study 
examining saliva visco-adhesive properties and correlating with patient reported 
measures.  Weak or no correlation between patients’ assessment of xerostomia and 
salivary flow rate has previously been reported by several authors [5, 21 & 37]. The 
reasons for this and for the current results are unclear. A possible explanation may 
be that subjective xerostomia assessments in this study and others encompass all 
components contributing to the patients’ feeling of xerostomia whereas the 
objective measures of salivary flow rate or visco-adhesive properties isolate only that 
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particular aspect. To find a relevant correlation one may have to assess all objective 
components that contribute to the symptom of xerostomia.  This is beyond the 
scope of this study but this finding reinforces the importance of including patient 
reported measures in xerostomia studies.  
 
This study has demonstrated that saliva became more adhesive and viscous as RT 
progressed. However, the addition of LMS-611 at concentrations of 10mg/ml and 
20mg/ml reversed this change in visco-adhesive properties and restored its fluidity. 
The addition of saline to saliva samples did not, therefore ruling out the possibility 
that the addition of fluid alone, rather than an active mucokinetic preparation, may 
cause this change. Indeed the data suggests that the addition of saline to saliva 
samples makes the saliva more visco-adhesive than with no additive at all. 
Furthermore LMS-611 at concentrations of 2.5mg/ml and 5mg/ml had little or no 
impact on the saliva properties. The 10mg/ml and 20mg/ml preparations 
demonstrated significant efficacy. As a result the 2.5mg/ml and 5mg/ml 
concentrations have been removed from the forthcoming clinical study.  The effects 
of LMS-611 in concentrations of 10mg/ml and 20mg/ml on xerostomia will be 
assessed in-vivo. 
 
Previous pre-clinical work with LMS-611 [unpublished data] has shown that it acts on 
the biophysical properties of saliva by changing its external bonds and therefore its 
visco-adhesive properties. The effect is almost instantaneous and can be seen in the 
video [Online Resource 2, Addition of LMS-611 to Mucin]. 
 
Although parotid sparing IMRT is now commonplace in H&N cancer, leading to 
improvements in late toxicities and quality of life, RIX remains a significant clinical 
problem for many patients. Rates of clinically significant late xerostomia up to 40% 
are seen, despite constraining the dose delivered to the contralateral parotid gland. 
[15, 16, 37-39] For some patients with bilateral cervical nodal metastases or bulky 
primary disease crossing midline, it is not possible to deliver parotid sparing RT for 
fear of compromising dose to tumour and subsequent disease control. Most of these 
patients will develop RIX as a late, permanent and significant toxicity. Furthermore, 
many centres are not yet able to offer IMRT to all patients who might benefit from it. 
In April 2013 it was reported that only 22.3% of all patients receiving radical RT in 
England were treated with IMRT [40]. Globally it is estimated that less than 10% of 
the population have access to this technology [41]. 
 
Currently available interventions for RIX remain unsatisfactory with no evidence that 
any topical therapy is effective in relieving the symptom of dry mouth [8]. Salivary 
stimulants are more effective in treating RT induced hypo-salivation than salivary 
substitutes, hyperbaric oxygen, or acupuncture but may cause significant side 
effects.  Other novel interventions which aim to regenerate salivary gland tissue post 
radiotherapy e.g. stem cell transplant and gene therapy remain at a preliminary 
investigational stage and are likely to take many years to be widely available in 
clinical practice.  [16] Salivary gland transfer is a further option but is also 
experimental, requires a surgical procedure and may not be suitable for all patients. 
[42] There remains a need, therefore, for further studies examining topical 
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interventions for RIX and in particular to assess patient reported symptom scores 
and quality of life measures when assessing efficacy [35].  
 
LMS-611 oral spray is an attractive option for the treatment of RIX. Its mode of 
action is biophysical rather than pharmacological and therefore has an excellent 
safety and side effect profile [unpublished data].  Compared to other novel 
approaches, the timeline for its development from bench to bedside is significantly 
shorter; it is non-invasive and can be made widely available.   This warrants in-vivo 
analysis of the effects of LMS-611 upon RIX.  
  
 
CONCLUSIONS 
Saliva becomes more adhesive and viscous as RT progresses. There is wide inter-
patient variability in these saliva properties pre-treatment.   
Patient reported xerostomia worsens as RT progresses with the largest change 
within the first two weeks of radiotherapy. Inter-patient variability in reported 
xerostomia remains constant throughout treatment. 
No relevant correlation between patient reported xerostomia and laboratory 
measurements of saliva properties was demonstrated.  
This data suggests that concentrations of 10mg/ml and 20mg/ml merit in-vivo 
testing in a forthcoming clinical study. 
Current topical measures for the management of RIX in H&N cancer are 
unsatisfactory and new interventions for RIX remain relevant in the parotid-sparing 
IMRT era.   
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TABLES      
 
Table 1: Patient Demographics 
Total Number of Patients 30 
Mean Age     (years) 54.8 
Age range     (years) 42-67 
Gender            Male 
                         Female 
24 (80%) 
6    (20%) 
Stage               II 
                         III 
                         IV 
1    (3.3%) 
4    (13.3%) 
25 (83.3%) 
Radiotherapy alone 
Chemoradiotherapy 
3    (10%) 
27 (90%) 
 
 
Table 2: Inclined Plane Test Results  
 Time point during radiotherapy 
Baseline Week 2 Week 4 Week 6 
 
 
 
 
 
 
 
 
Inclined 
Plane  
Test 
(seconds) 
Mean (SD) 31.3 
(22.5) 
49.7 
(14.0) 
51.1 
(14.9) 
55.7 (9.0) 
Median  
(IQR) 
31.0  
(6.8, 
56.0) 
57.5 
(44.8, 
60.0) 
60.0 
(42.2, 
60.0) 
60.0 
(57.2, 
60.0) 
Range 2.0 – 
60.0 
16.0 – 
60.0 
5.0 – 
60.0 
32.0 – 
60.0 
Mean difference 
from baseline 
 18.3 19.1 25.3 
Comparison to 
baseline using 
wilcoxon test 
p=0.001 p=0.003 p<0.001 
Comparison to 
baseline using 
proportional 
hazards 
regression 
 
p=0.005 
 
p=0.004 
 
p<0.001 
Mean difference 
from previous 
visit 
18.3 3.3 5.5 
Comparison to 
previous visit 
using wilcoxon 
test 
p=0.001 p=0.250 p=0.297 
Number samples 
assessable 
28 26 22 22 
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Table 3: Inclined Plane Test Results with addition saline or LMS-611 
 Time point during radiotherapy 
Week 2 Week 4 Week 6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Inclined 
Plane 
Test 
(seconds) 
 
Untreated 
 
NOBS  
Mean (SD) 
Median 
(IQR) 
 
26  
49.7 (14.0) 
57.5 (44.8, 60.0) 
 
 
22  
51.1 (14.9) 
60.0 (42.2, 60.0) 
 
 
22  
55.7 (9.0) 
60.0 (57.2, 60.0) 
 
Saline 
 
NOBS  
Mean (SD) 
Median 
(IQR) 
 
 
23  
59.0 (4.4) 
60.0 (60.0, 60.0) 
 
 
18  
59.3 (2.4) 
60.0 (60.0, 60.0) 
 
 
22  
60.0 (0.0) 
60.0 (60.0, 60.0) 
 
 
LMS-611  
2.5 mg/ml 
 
NOBS  
Mean (SD) 
Median 
(IQR) 
 
 
23  
57.6 (5.3) 
60.0 (59.0, 60.0) 
 
 
17  
58.6 (4.9) 
60.0 (60.0, 60.0) 
 
 
18  
58.9 (4.7) 
60.0 (60.0, 60.0) 
 
 
LMS-611  
5 mg/ml 
 
NOBS  
Mean (SD) 
Median 
(IQR) 
 
 
23  
47.2 (18.4) 
60.0 (36.0, 60.0) 
 
16  
54.4 (10.3) 
60.0 (53.2, 60.0) 
 
 
19  
58.3 (7.3) 
60.0 (60.0, 60.0) 
 
 
LMS-611 
10 mg/ml 
 
NOBS  
Mean (SD) 
Median 
(IQR) 
 
 
23  
24.2 (20.2) 
16.0 (10.5, 37.0) 
 
 
18  
17.3 (14.6) 
14.5 (10.0, 17.8) 
 
 
22  
32.5 (16.7) 
29.0 (18.8, 44.5) 
 
 
LMS-611  
20 mg/ml 
 
NOBS  
Mean (SD) 
Median 
(IQR) 
 
 
23  
4.3 (2.9) 
3.0 (2.0, 6.0) 
 
 
18  
7.1 (8.0) 
4.0 (2.0, 9.0) 
 
 
22  
11.0 (9.6) 
8.5 (5.2, 12.8) 
 
NOBS = Number of Observations Assessable  
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Table 4: All inclined plane test results with addition of LMS-611 or saline, adjusted for 
week of radiotherapy. Cox proportional hazards model. 
 
 Hazard Ratio 95% Confidence 
Interval 
p-value 
Saline vs. untreated 0.115 ( 0.045, 0.294) p<0.001 
2.5 mg/ml vs. untreated 0.283 ( 0.125, 0.639) p=0.002 
5 mg/ml vs. untreated 0.593 ( 0.337, 1.042) p=0.069 
10 mg/ml vs. untreated 4.957 ( 3.132, 7.846) p<0.001 
20 mg/ml vs. untreated 30.687 (17.852, 52.750) p<0.001 
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